Tegelased 3
  • Parm, Tiit- Vessingi et.al. 2023. Effect of early directed implementation of family-integrated care measures on colonisation with Enterobacteriaceae in preterm neonates in NICU
  • Soeorg et.al. 2022. Estimation of cefepime, piperacillin, and tazobactam clearance with iohexol-based glomerular filtration rate in paediatric patients
  • Ciesielski et.al. 2022. Late-onset neonatal sepsis: genetic differences by sex and involvement of the NOTCH pathway.
  • Jacobs et.al. 2022. What babies need: accelerating access to current and novel antiretroviral drugs in neonates through pharmacokinetic studies
  • Kopsidas et.al. 2022. Hand Hygiene Compliance Rates in 9 Pediatric Intensive Care Units Across Europe: Results from the Reducing Antimicrobial use and Nosocomial Infections in Kids Network.
  • Hill et.al. 2022. Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial
  • Koivumagi et.al. 2022. Norovirus strains among children aged 0-18 years hospitalized with acute gastroenteritis in Estonia 2015-2016
  • Soeorg et.al. 2021. Glomerular filtration rate in children and young adults with haemato-oncological disease and infection is best described by three-compartmental iohexol model
  • Padari et.al. 2021. Ampicillin Pharmacokinetics During First Week of Life in Preterm and Term Neonates.
  • Tang et.al. 2021. Drug Clearance in Neonates: A Combination of Population Pharmacokinetic Modelling and Machine Learning Approaches to Improve Individual Prediction
  • Williams et.al. 2021. Harmonising regulatory approval for antibiotics in children
  • Cook et. al. 2021. Improving empiric antibiotic prescribing in pediatric bloodstream infections: a potential application of weighted-incidence syndromic combination antibiograms (WISCA)
  • Lutsar et.al. 2020. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): A randomised controlled trial.
  • Jõgi et.al. 2020. Dynamics of pertussis toxin IgG after symptomatic pertussis in children and adults
  • Tiit-Vesingi et al. 2020. Staphylococcus epidermidis’e suur genotüübiline mitmekesisus perekeskses vastsündinute intensiivravi osakonnas
  • Tiit et.al. 2019. Rinnapiima kolonisatsioon mecA-positiivsete koagulaasnegatiivsete stafülokokkidega kolmes vastsündinute intensiivravi osakonnas
  • Jõgi et.al. 2019. Läkaköha toksiini vastaste antikehade püsimine lastel ja täiskasvanutel pärast läkaköha põdemist
  • Hallik et al. 2019. Population pharmacokinetics and pharmacodynamics ofdobutamine in neonates on the first days of life
  • Soeorg et al. 2019. Genetic Relatedness of Staphylococcus haemolyticus in Gut and Skin of Preterm Neonates and Breast Milk of Their Mothers
  • Mesek et al. 2019. Medicines prescription patterns in European neonatal units.
  • Jacqz-Aigrain et al. 2019. Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants
  • Hallik et al. 2019. Population Pharmacokinetics and Dosing of Milrinone After Patent Ductus Arteriosus Ligation in Preterm Infants.
  • Telling et al. 2018. Multidrug resistant Pseudomonas aeruginosa in Estonian hospitals.
  • Soeorg et al. 2018. Higher intake of coagulase-negative staphylococci from maternal milk promotes gut colonization with mecA-negative Staphylococcus epidermidis in preterm neonates.
  • Germovsek et al. 2018. Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies.
  • Soeorg et al. 2018. Genetic Relatedness of Staphylococcus haemolyticus in Gut and Skin of Preterm Neonates and Breast Milk of Their Mothers.
  • Padari et al. 2018. Pharmacokinetics of penicillin G in preterm and term neonates.
  • Pansa et al. 2018. Evaluating Safety Reporting in Paediatric Antibiotic Trials, 2000-2016: A Systematic Review and Meta-Analysis.
  • Bassler et al. 2018. Long-Term Effects of Inhaled Budesonide for Bronchopulmonary Dysplasia.
  • Jõgi et al. 2018. Pertussis and parapertussis in children and adults with a persistent cough: an observational study.
  • Kogermann et al. 2017. Age-appropriate formulations including pharmaceutical excipients in neonatal medicines.
  • Thompson et al. 2017. Global shortage of neonatal and paediatric antibiotic trials: rapid review.
  • Pansa et al. 2017. Evaluating Safety Reporting in Paediatric Antibiotic Trials, 2000-2016: A Systematic Review and Meta-Analysis.
  • Tasa et al. 2017. DosOpt: A Tool for Personalized Bayesian Dose Adjustment of Vancomycin in Neonates.
  • Veigure et al. 2017. A highly sensitive method for the simultaneous UHPLC-MS/MS analysis of clonidine, morphine, midazolam and their metabolites in blood plasma using HFIP as the eluent additive.
  • Neubert et al. 2017. The CLOSED trial; CLOnidine compared with midazolam for SEDation of paediatric patients in the intensive care unit: study protocol for a multicentre randomised controlled trial.
  • Soeorg et al. 2017. The role of breast milk in the colonization of neonatal gut and skin with coagulase-negative staphylococci.
  • Hallik et al. 2017. Dosing of Milrinone in Preterm Neonates to Prevent Postligation Cardiac Syndrome: Simulation Study Suggests Need for Bolus Infusion.
  • Soeorg et al. 2017. Coagulase-Negative Staphylococci in Human Milk From Mothers of Preterm Compared With Term Neonates.
  • Draper et al. 2017. Variability in Very Preterm Stillbirth and In-Hospital Mortality Across Europe.
  • Raiskila et al. 2016. Corrigendum to "Parent and nurse perceptions on the quality of family-centered care in 11 European NICUs".
  • Veigure et al. 2016. A highly sensitive method for the simultaneous UHPLC-MS/MS analysis of clonidine, morphine, midazolam and their metabolites in blood plasma using HFIP as the eluent additive.
  • Takkis et al 2016. Signal Enhancement in the HPLC-ESI-MS/MS analysis of spironolactone and its metabolites using HFIP and NH4F as eluent additives.
  • Soeorg et al. 2016. Molecular epidemiology of Staphylococcus epidermidis in neonatal intensive care units.
  • Padari et al. 2016. Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?
  • Folgori et al. 2016. Harmonisation in study design and outcomes in paediatric antibiotic clinical trials: a systematic review.
  • Brauer et al. 2016. Plasmid with colistin resistance gene mcr-1 in ESBL-producing Escherichia coli strains isolated from pig slurry in Estonia.
  • Germovsek et al. 2016. Development and Evaluation of a Gentamicin Pharmacokinetic Model That Facilitates Opportunistic Gentamicin Therapeutic Drug Monitoring in Neonates and Infants.
  • Nellis et al. 2016. Product Substitution as a Way Forward in Avoiding Potentially Harmful Excipients in Neonates.
  • Mulla et al. 2015. An observational study of blood concentrations and kinetics of methyl- and propyl-parabens in neonates.
  • Turner et al. 2015. Pediatric microdose and microtracer studies using (14) C in Europe.
  • Garner et al. 2015. Observational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis.
  • Carbajal et al. 2015. Sedation and analgesia practices in neonatal intensive care units (EUROPAIN): results from a prospective cohort study.
  • Bassler et al. 2015. Early Inhaled Budesonide for the Prevention of Bronchopulmonary Dysplasia.
  • Metsvaht et al. 2015. High variability in the dosing of commonly used antibiotics revealed by a Europe-wide point prevalence study: implications for research and dissemination.
  • Parm et al. 2015. Gut colonization by aerobic microorganisms is associated with route and type of nutrition in premature neonates.
  • Nellis et al. 2015. Potentially harmful excipients in neonatal medicines: a pan-European observational study.
  • Turner et al. 2014. Risk assessment of neonatal excipient exposure: Lessons from food safety and other areas.
  • Mitt et al. 2014. Five-year prospective surveillance of nosocomial bloodstream infections in an Estonian paediatric intensive care unit.
  • Romantsik et al. 2014. The effects of olfactory stimulation and gender differences on pain responses in full-term infants.
  • Hallik et al. 2014. Different course of lung disease in two siblings with novel ABCA3 mutations.
  • Drell et al. 2014. The development of gut microbiota in critically ill extremely low birth weight infants assessed with 16S rRNA gene based sequencing.
  • Lutsar et al. 2014. Current management of late onset neonatal bacterial sepsis in five European countries.
  • Nellis et al. 2014. Comparison of two alternative study designs in assessment of medicines utilisation in neonates.
  • Jõgi et al. 2014. Seroprevalence of IgG antibodies to pertussis toxin in children and adolescents in Estonia.
  • Lutsar et al. 2014. Treatment option for sepsis in children in the era of antibiotic resistance.
  • Soeorg et al. 2013. Group A rotavirus genotypes circulating prior to implementation of a National Immunization Program in Estonia.
  • Versporten et al. 2013. The antibiotic resistance and prescribing in European Children project: a neonatal and pediatric antimicrobial web-based point prevalence survey in 73 hospitals worldwide.
  • Turnet et al. 2013. European Study of Neonatal Exposure to Excipients: An update.
  • Garazzino et al. 2013. New antibiotics for paediatric use: A review of a decade of regulatory trials submitted to the European Medicines Agency from 2000-Why aren't we doing better?
  • Toome et al. 2013. Follow-up study of 2-year-olds born at very low gestational age in Estonia.
  • Soeorg et al. 2013. Genetic relatedness of coagulase-negative Staphylococci from gastrointestinal tract and blood of preterm neonates with late-onset sepsis.
  • Brilene et al. 2013. In vitro synergy of oxacillin and gentamicin against coagulase-negative staphylococci from blood cultures of neonates with late-onset sepsis.
  • Oeser et al. 2013. Clinical trials in neonatal sepsis.
  • Lass et al. 2013. Antibiotic prescription preferences in paediatric outpatient setting in Estonia and Sweden.
  • Esposito et al. 2012. Antibiotic Therapy for Pediatric Community-Acquired Pneumonia: Do We Know When, What and For How Long to Treat?
  • Toome et al. 2012. Changes in care and short-term outcome for very preterm infants in Estonia.
  • Padari et al. 2012. Short versus long infusion of meropenem in very-low-birth-weight neonates.
  • Lass et al. 2012. Hospitalised neonates in Estonia commonly receive potentially harmful excipients.
  • Parm et al. 2011. Mucosal surveillance cultures in predicting Gram-negative late-onset sepsis in neonatal intensive care units.
  • Parm et al. 2011. Risk factors associated with gut and nasopharyngeal colonization by common Gram-negative species and yeasts in neonatal intensive care units patients.
  • Heidmets (Kõrgvee) et al. 2011. Blood loss related to participation in pharmacokinetic study in preterm neonates.
  • Metsvaht et al. 2011. Ampicillin versus penicillin in the empiric therapy of extremely low-birthweight neonates at risk of early onset sepsis.
  • Lutsar et al. 2011. Meropenem vs standard of care for treatment of late onset sepsis in children of less than 90 days of age: study protocol for a randomised controlled trial.
  • Yakkundi et al. 2011. Use of dried blood spots to study excipient kinetics in neonates.
  • Lass et al. 2011. Off label use of prescription medicines in children in outpatient setting in Estonia is common.
  • Lass et al. 2011. Drug utilisation pattern and off-label use of medicines in Estonian neonatal units.
EST